HK Stock Market Move | VIGONVITA-B(02630) vomited more than 18% on the day after its launch, still trading at about double its IPO price.

On the day after its listing, VIGONVITA-B (02630) fell more than 18%. The stock had surged over 145% the previous trading day, and the current stock price is still about double the IPO price of HK$33.37, standing at HK$67.05 as of the time of writing, a decrease of 18.23%, with a turnover of HK$50.82 million. It is reported that WANGSHANWANGSHUI was established in 2013 and is a biopharmaceutical company focusing on three major treatment areas: neurology, reproductive health, and viral infections. As of October 21, 2025, the company has developed a diversified pipeline of 9 innovations, with 2 in the commercialization stage, 4 in the clinical stage, and 3 in the preclinical stage. In addition to the innovative drug pipeline, the company also has a portfolio of generic drugs, with 3 drugs in or near the commercialization stage. Currently, WANGSHANWANGSHUI's two core products are LV232 and TPN171. In terms of finances, the company recorded revenues of RMB 200 million, RMB 11.832 million, RMB 3.224 million, and RMB 12.958 million in 2023, 2024, and the first four months of 2025 respectively. Additionally, the company recorded a net loss of RMB 218 million in 2024 and a net profit of RMB 6.427 million in 2023. The prospectus explains that this fluctuation is mainly due to a decrease in revenue.